Solving for Early Cancer Detection – Freenome
Why This Is Important While there isn't yet an absolute way of eradicating cancer, early detection is the best solution we have, at least for now. There are current screening…
Augtyro to treat non-small cell lung cancer
Drug Name: Augtyro Active Ingredient: repotrectinib Indication: To treat ROS1-positive non-small cell lung cancer Approval Date: 11/15/2023 Company: Bristol-Myers Squibb Company More: https://accessdata.fda.gov/drugsatfda_docs/label/2023/218213s000lbl.pdf
Fruzaqla to treat colorectal cancer
Drug Name: Fruzaqla Active Ingredient: fruquintinib Indication: To treat refractory, metastatic colorectal cancer Approval Date: 11/8/2023 Company: Takeda Pharmaceuticals America, IncMore: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217564s000lbl.pdf
Proscia helps to detect cancer cells
A digital pathology platform that uses AI to detect patterns in cancer cells. Description The company’s software helps pathology labs enhance data management and uses AI-powered image analysis to connect…
Freenome helps test for cancer
Uses AI systems in screenings, blood test and other diagnostic procedures to test for cancer. Description Freenome is developing next-generation blood tests for early cancer detection, powered by our multiomics…
Merck’s Keytruda gets FDA nod for expanded use in lung cancer
The U.S. Food and Drug Administration on Monday approved the expanded use of Merck & Co's blockbuster immunotherapy Keytruda in early-stage patients with non-small cell lung cancer who can get their…
Posluma for prostate cancer imaging
Drug Name: Posluma Indications: To use with positron emission tomography imaging in certain patients with prostate cancer. Active Ingredient: Flotufolastat F 18 Company: Blue Earth Diagnostics Ltd. Approval Date: 5/25/2023…
Tempus receives FDA approval for xT CDx, a NGS-Based In Vitro Diagnostic Device
Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s first Premarket Approval (PMA) application for its…
Orserdu to treat advanced or metastatic breast cancer
Drug Name: Orserdu Indications: To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine…
Krazati to NSC lung cancer
Drug Name: Krazati Active Ingredient: adagrasib Indications: To treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer in adults who have received at least one prior systemic therapy…